Ackermans & van Haaren: Nextensa might aim for ‘Proximus Towers' landmark project. D'Ieteren: Auto CEO sees Belgian new car market at 420k in 2025, down 6% YoY. Fastned: Preview of 4Q24 trading update. Proximus: HQ sale likely at price materially lower than expected. Randstad: 4Q24F results due 12 Feb, consensus released, negative earnings momentum. WDP: Sizeable acquisition in Belgium
Fastned reported a 4Q23 trading update in October where revenue and gross profit came in higher vs our estimates. As a result, we make small upward revisions to our forecasts. We keep our HOLD rating but raise our target price to €20.5 per share (from €17.50 previously).
Ageas: Circling around Direct Line, Aviva edges ahead. D'Ieteren: TVH distribution footprint restructured in Belgium. Dutch insurance - Achmea Life JV with PE firm, aiming to take 20% of Dutch buyouts. Elia: FY24 guidance up. Prosus: 1H25 Preview. Renewi: Macquarie is back. Sif Group: First monopile rolls out of new factory
>Conclusion: The >20% revenue growth path is continuing well - The 3Q24 net revenue growth of +21% yoy (cc) was 1-2pp less than we expected. As a consequence of the reduction of business of one single low revenue (high TPV / low take rate) client the Q3 TPV was lower and the take rate was higher. Most important is that the revenue growth remains at the >+20% level. The limited FTE growth and focus on profitable clients increases our confidence in the EBITDA margin exp...
Volumes continue to be soft, if stable, for “legacy” players with Nexi reporting 3% y/y volume growth in Q3 (as in Q2) - identical trends to Worldline (see Q3 write up HERE) . Adyen volumes are of course well ahead; whilst legacy players confront macro pressures, and more, Adyen’s ability to gain share is both notable – and indeed essential for the equity story.
After a rollercoaster day, the stock seems to have landed in a sensible place: small miss, small down. We thought the earnings call was solid, as good as we were likely to get, management sounding confident on accelerating growth into FY 25.
>Conclusion: Net revenue growth +21% cc being -just- 1% less than expected - The 3Q24 net revenue growth was +21% cc being -just- 1% less than expected. We understand that with a high growth company even 1% less is relevant but we do not have to change our revenue estimates for the future in any material way. We keep our Outperform as the +21% constant revenue growth show the business model is working well. Net revenue growth Q3 +21% at cc vs +22% expect...
With 2 changes in our Dynamic Top Pick list (we add Azelis and we remove Solvay) we maintain a defensive stance on the market for 2H24. The long anticipated interest rate cuts by central banks have finally started. The Trump election victory in the US does not bode well for European stocks as he favours a protectionist course. Although industrial companies with a US base could actually benefit. Cleantech names with exposure to the US could also suffer (unless owned by E.Musk). We expect the US ...
Following solid H1s, and a rare and supportive near-term steer for H2, consensus expectations have stayed pretty rooted to the bottom of the guide range for revenue for both Q3 (reported Thursday/tomorrow) and Q4 (21%, 20% y/y respectively). Downside risk to estimates for H2 looks limited.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.